No one is going to pay 100 million for ESS without first having a successful phase 2 trial done- too much risk. That will take 2 years if you include at least 6 months to negotiate a partnership or sale. At 500k per month in cash burn (6 million per year) and another 7- 10 million owed to lenders today we need about 15- 20 million right now to clean up books and get us to that point. No one is going to lend us money without having a floorless clause because they know they would lose everything just like us shareholders as the toxics dilute us into oblivion. That is why GC is offloading ESS to another entity so he can fund it separately- great for ESS, but not AMBS shareholders. Even if AMBS got $100 million in 2 years,if we have a billion shares outstanding by then which we could or even more, that's only 10 cents a share- exactly where we are currently. The only hope we have at this point is for ESS to be licensed to China for a big upfront payment.
(4)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links